In Palo Alto, California on December 18, 2025, Kodiak Sciences Inc. (Nasdaq: KOD), a biotech company focused on retinal treatments, has completed the planned closing of a recent business initiative. The company is dedicated to pioneering innovative therapies for eye diseases.